| Q41835781 | (18)F-FDG PET/CT of advanced gastric carcinoma and association of HER2 expression with standardized uptake value |
| Q44885327 | Are biopsy specimens predictive of HER2 status in gastric cancer patients? |
| Q38819670 | Cardiotoxicity associated with targeted cancer therapies |
| Q47164059 | Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy? |
| Q38827897 | Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory |
| Q36548702 | Cisplatin resistance in gastric cancer cells is associated with HER2 upregulation-induced epithelial-mesenchymal transition |
| Q33943812 | Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas |
| Q53134672 | Clinicopathological and prognostic significance of HER2 overexpression in gastric cancer: a meta-analysis of the literature. |
| Q91865170 | Clinicopathological features and Borrmann classification associated with HER2-positive in primary gastric cancer |
| Q33913610 | Comparison of HER2 expression between primary colorectal cancer and their corresponding metastases |
| Q26801167 | Correlation of human epidermal growth factor receptor protein expression and colorectal cancer |
| Q38087507 | Cytoplasmic Overexpression of HER2: a Key Factor in Colorectal Cancer. |
| Q39686854 | Early response to ErbB2 over-expression in polarized Caco-2 cells involves partial segregation from ErbB3 by relocalization to the apical surface and initiation of survival signaling |
| Q47950050 | ErbB family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery. |
| Q53091400 | Expression analysis of heat shock protein 90 (HSP90) and Her2 in colon carcinoma. |
| Q54501568 | Expression and association of HER2 with prognosis in early-stage (T1-T2N0M0) non-small cell lung cancer. |
| Q33626875 | Frequency of HER2/neu overexpression in adenocarcinoma of the gastrointestinal system |
| Q37109905 | Genomic markers of panitumumab resistance including ERBB2/ HER2 in a phase II study of KRAS wild-type (wt) metastatic colorectal cancer (mCRC). |
| Q37708897 | HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives |
| Q28078111 | HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists |
| Q43825401 | HER2 and immunotherapy using monoclonal antibodies in colorectal cancer. |
| Q38314355 | HER2 assessment by silver in situ hybridization: where are we now? |
| Q38364900 | HER2 expression status in diverse cancers: review of results from 37,992 patients |
| Q50964844 | HER2 protein expression and HER2 gene amplification are infrequent in small intestinal carcinomas. |
| Q34499615 | HER2/neu testing in primary colorectal carcinoma |
| Q37824265 | Her-2/neu testing and therapy in gastroesophageal adenocarcinoma |
| Q31059013 | Integration of DNA copy number alterations and transcriptional expression analysis in human gastric cancer. |
| Q30856729 | Is overexpression of HER-2 a predictor of prognosis in colorectal cancer? |
| Q39861972 | KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer. |
| Q90279899 | KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer - practical implications for the clinician |
| Q86876904 | Over-expression of Her-2 in colorectal cancer tissue, but not in serum, constitutes an independent worse prognostic factor |
| Q38653309 | Pertuzumab in gastrointestinal cancer |
| Q53128686 | Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. |
| Q38116869 | RAS signaling pathways, mutations and their role in colorectal cancer |
| Q38199128 | Recent advances and future trends in the targeted therapy of metastatic gastric cancer |
| Q64116155 | Significance of HER2 protein expression and gene amplification in colorectal adenocarcinomas |
| Q34585338 | Significance of human epidermal growth factor receptor 2 expression in colorectal cancer |
| Q91291948 | Somatic mutation profiling and HER2 status in KRAS-positive Chinese colorectal cancer patients |
| Q37725990 | Targeted immunotherapy for colorectal cancer: monoclonal antibodies and immunotoxins |
| Q54962247 | Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. |
| Q36034067 | The clinical significance of HER2 protein amplification/expression in urinary bladder lesion |
| Q33764191 | The validation of a novel method combining both HER2 immunohistochemistry and HER2 dual-colour silver in situ hybridization on one slide for gastric carcinoma testing |
| Q33618553 | Tumor suppressor role of miR-3622b-5p in ERBB2-positive cancer |